Aberrantly elevated redox sensing factor Nrf2 promotes cancer stem cell survival via enhanced transcriptional regulation of ABCG2 and Bcl-2/Bmi-1 genes

Oncology Reports

Volumn 34, Issue 5, 2015, Pages 2296-2304

  Jia, Yan ^a   Chen, Jun ^a   Zhu, He ^a   Jia, Zan Hui ^a   Cui, Man Hua ^a  

^a THE SECOND HOSPITAL OF JILIN UNIVERSITY   (China)

Author keywords

Anti apoptotic genes; Cancer stem cells; Cell proliferation; Drug resistance; Nrf2

Indexed keywords

BMI1 PROTEIN; BREAST CANCER RESISTANCE PROTEIN; CISPLATIN; FLUOROURACIL; OXALIPLATIN; PACLITAXEL; PROTEIN BCL 2; TRANSCRIPTION FACTOR NRF2; ABCG2 PROTEIN, HUMAN; ANTINEOPLASTIC AGENT; BCL2 PROTEIN, HUMAN; BMI1 PROTEIN, HUMAN; NFE2L2 PROTEIN, HUMAN; TUMOR PROTEIN;

ABCG2 GENE; ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BCL 2 GENE; BMI 1 GENE; CANCER RECURRENCE; CANCER RESISTANCE; CANCER STEM CELL; CANCER THERAPY; CARCINOGENICITY; CELL DENSITY; CELL PROLIFERATION; CELL SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; DOWN REGULATION; DRUG TRANSPORT; FEMALE; GENE TARGETING; HUMAN; HUMAN TISSUE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; SURVIVAL RATE; TRANSCRIPTION REGULATION; UPREGULATION; ANIMAL; CANCER TRANSPLANTATION; DRUG RESISTANCE; GENE EXPRESSION; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MULTIDRUG RESISTANCE; NONOBESE DIABETIC MOUSE; OXIDATION REDUCTION REACTION; PATHOLOGY; PHYSIOLOGY; SCID MOUSE; UTERINE CERVIX TUMOR;

ADULT; ANIMALS; ANTINEOPLASTIC AGENTS; ATP BINDING CASSETTE TRANSPORTER, SUB-FAMILY G, MEMBER 2; CELL SURVIVAL; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE EXPRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICE, INBRED NOD; MICE, SCID; NEOPLASM PROTEINS; NEOPLASM TRANSPLANTATION; NEOPLASTIC STEM CELLS; NF-E2-RELATED FACTOR 2; OXIDATION-REDUCTION; POLYCOMB REPRESSIVE COMPLEX 1; PROTO-ONCOGENE PROTEINS C-BCL-2; UTERINE CERVICAL NEOPLASMS;

EID: 84941944957     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2015.4214     Document Type: Article

References (34)

1. Bansal N, Herzog TJ, Shaw RE, Burke WM, Deutsch I and Wright JD: Primary therapy for early-stage cervical cancer: Radical hysterectomy vs radiation. Am J Obstet Gynecol 201: 485.e1-485.e9, 2009.
2. Kosmas C, Mylonakis N, Tsakonas G, Vorgias G, Karvounis N, Tsavaris N, Daladimos T, Kalinoglou N, Malamos N, Akrivos T, et al: Evaluation of the paclitaxel-ifosfamide-cisplatin (TIP) combination in relapsed and/or metastatic cervical cancer. Br J Cancer 101: 1059-1065, 2009.
3. Zhang SL, Wang YS, Zhou T, Yu XW, Wei ZT and Li YL: Isolation and characterization of cancer stem cells from cervical cancer HeLa cells. Cytotechnology 64: 477-484, 2012.
4. Bapat SA, Mali AM, Koppikar CB and Kurrey NK: Stem and progenitor-like cells contribute to the aggressive behavior of human epithelial ovarian cancer. Cancer Res 65: 3025-3029, 2005.
5. Collins AT, Berry PA, Hyde C, Stower MJ and Maitland NJ: Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res 65: 10946-10951, 2005.
6. Olempska M, Eisenach PA, Ammerpohl O, Ungefroren H, Fandrich F and Kalthoff H: Detection of tumor stem cell markers in pancreatic carcinoma cell lines. Hepatobiliary Pancreat Dis Int 6: 92-97, 2007.
7. Tu SM, Lin SH and Logothetis CJ: Stem-cell origin of metastasis and heterogeneity in solid tumours. Lancet Oncol 3: 508-513, 2002.
8. Szotek PP, Pieretti-Vanmarcke R, Masiakos PT, Dinulescu DM, Connolly D, Foster R, Dombkowski D, Preffer F, Maclaughlin DT and Donahoe PK: Ovarian cancer side population defines cells with stem cell-like characteristics and Mullerian inhibiting substance responsiveness. Proc Natl Acad Sci USA 103: 11154-11159, 2006.
9. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ and Clarke MF: Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA 100: 3983-3988, 2003.
10. Goodell MA, Brose K, Paradis G, Conner AS and Mulligan RC: Isolation and functional properties of murine hematopoietic stem cells that are replicating in vivo. J Exp Med 183: 1797-1806, 1996.
11. Zhou S, Schuetz JD, Bunting KD, Colapietro AM, Sampath J, Morris JJ, Lagutina I, Grosveld GC, Osawa M, Nakauchi H, et al: The ABC transporter Bcrp1/ABCG2 is expressed in a wide variety of stem cells and is a molecular determinant of the side-population phenotype. Nat Med 7: 1028-1034, 2001.
12. Hirschmann-Jax C, Foster AE, Wulf GG, Nuchtern JG, Jax TW, Gobel U, Goodell MA and Brenner MK: A distinct 'side population' of cells with high drug efflux capacity in human tumor cells. Proc Natl Acad Sci USA 101: 14228-14233, 2004.
13. Wulf GG, Wang RY, Kuehnle I, Weidner D, Marini F, Brenner MK, Andreeff M and Goodell MA: A leukemic stem cell with intrinsic drug efflux capacity in acute myeloid leukemia. Blood 98: 1166-1173, 2001.
14. Qin ZL, Zheng XX and Xu YH: Increased angiogenesis and decreased programmed cell death increases the risk of uterine cervical cancer. Drug Res: Oct 21, 2014 (Epub ahead of print).
15. Yang B, Ma YF and Liu Y: Elevated expression of Nrf-2 and ABCG2 involved in multi-drug resistance of lung cancer SP cells. Drug Res: Nov 4, 2014 (Epub ahead of print).
16. Zhang QH, Dou HT, Xu P, Zhuang SC and Liu PS: Tumor recurrence and drug resistance properties of side population cells in high grade ovary cancer. Drug Res 65: 153-157, 2015.
17. Shi Y, Fu X, Hua Y, Han Y, Lu Y and Wang J: The side population in human lung cancer cell line NCI-H460 is enriched in stem-like cancer cells. PLoS One 7: e33358, 2012.
18. Fan J, Li R, Zhang R, Liu HL, Zhang N, Zhang FQ and Dou KF: Effect of Bcl-2 and Bax on survival of side population cells from hepatocellular carcinoma cells. World J Gastroenterol 13: 6053-6059, 2007.
19. Park JR, Kim RJ, Lee YK, Kim SR, Roh KJ, Oh SH, Kong G, Kang KS and Nam JS: Dysadherin can enhance tumorigenesis by conferring properties of stem-like cells to hepatocellular carcinoma cells. J Hepatol 54: 122-131, 2011.
20. Shimamura T, Yasuda J, Ino Y, Gotoh M, Tsuchiya A, Nakajima A, Sakamoto M, Kanai Y and Hirohashi S: Dysadherin expression facilitates cell motility and metastatic potential of human pancreatic cancer cells. Cancer Res 64: 6989-6995, 2004.
21. Kim RJ, Kim SR, Roh KJ, Park SB, Park JR, Kang KS, Kong G, Tang B, Yang YA, Kohn EA, et al: Ras activation contributes to the maintenance and expansion of Sca-1pos cells in a mouse model of breast cancer. Cancer Lett 287: 172-181, 2010.
22. Singh A, Wu H, Zhang P, Happel C, Ma J and Biswal S: Expression of ABCG2 (BCRP) is regulated by Nrf2 in cancer cells that confers side population and chemoresistance phenotype. Mol Cancer Ther 9: 2365-2376, 2010.
23. Bonnet D and Dick JE: Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med 3: 730-737, 1997.
24. Lapidot T, Sirard C, Vormoor J, Murdoch B, Hoang T, Caceres-Cortes J, Minden M, Paterson B, Caligiuri MA and Dick JE: A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature 367: 645-648, 1994.
25. Reya T, Morrison SJ, Clarke MF and Weissman IL: Stem cells, cancer, and cancer stem cells. Nature 414: 105-111, 2001.
26. Hass R, Giese G, Meyer G, Hartmann A, Dörk T, Köhler L, Resch K, Traub P and Goppelt-Strübe M: Differentiation and retrodifferentiation of U937 cells: Reversible induction and suppression of intermediate filament protein synthesis. Eur J Cell Biol 51: 265-271, 1990.
27. Salnikov AV, Gladkich J, Moldenhauer G, Volm M, Mattern J and Herr I: CD133 is indicative for a resistance phenotype but does not represent a prognostic marker for survival of non-small cell lung cancer patients. Int J Cancer 126: 950-958, 2010.
28. Itoh K, Chiba T, Takahashi S, Ishii T, Igarashi K, Katoh Y, Oyake T, Hayashi N, Satoh K, Hatayama I, et al: An Nrf2/small Maf heterodimer mediates the induction of phase II detoxifying enzyme genes through antioxidant response elements. Biochem Biophys Res Commun 236: 313-322, 1997.
29. Ramos-Gomez M, Kwak MK, Dolan PM, Itoh K, Yamamoto M, Talalay P and Kensler TW: Sensitivity to carcinogenesis is increased and chemoprotective efficacy of enzyme inducers is lost in nrf2 transcription factor-deficient mice. Proc Natl Acad Sci USA 98: 3410-3415, 2001.
30. Kwak MK, Kensler TW and Casero RA Jr: Induction of phase 2 enzymes by serum oxidized polyamines through activation of Nrf2: Effect of the polyamine metabolite acrolein. Biochem Biophys Res Commun 305: 662-670, 2003.
31. Kobayashi A, Kang MI, Okawa H, Ohtsuji M, Zenke Y, Chiba T, Igarashi K and Yamamoto M: Oxidative stress sensor Keap1 functions as an adaptor for Cul3-based E3 ligase to regulate proteasomal degradation of Nrf2. Mol Cell Biol 24: 7130-7139, 2004.
32. Zhang DD, Lo SC, Cross JV, Templeton DJ and Hannink M: Keap1 is a redox-regulated substrate adaptor protein for a Cul3-dependent ubiquitin ligase complex. Mol Cell Biol 24: 10941-10953, 2004.
33. Singh A, Misra V, Thimmulappa RK, Lee H, Ames S, Hoque MO, Herman JG, Baylin SB, Sidransky D, Gabrielson E, et al: Dysfunctional KEAP1-NRF2 interaction in non-small-cell lung cancer. PLoS Med 3: e420, 2006.
34. Shibata T, Ohta T, Tong KI, Kokubu A, Odogawa R, Tsuta K, Asamura H, Yamamoto M and Hirohashi S: Cancer related mutations in NRF2 impair its recognition by Keap1-Cul3 E3 ligase and promote malignancy. Proc Natl Acad Sci USA 105: 13568-13573, 2008.